Navigation Links
Data Show FluMist May Reduce Seasonal Influenza Burden Among,,,Children in School, Daycare Settings

New Economic Analyses of School and Daycare Study Outcomes Suggest Vaccinating Against Influenza May Produce Cost Savings for Community at Large

TORONTO, May 08, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc. announced today research results showing that use of FluMist(R) (Influenza Virus Vaccine Live, Intranasal) in daycare and school settings may help reduce the burden of seasonal influenza. Economic analyses applied to outcomes observed in previously completed clinical studies suggest that influenza vaccination may provide a beneficial cost savings to the community at large. The results were presented at the annual meeting of the Pediatric Academic Societies (PAS) taking place this week in Toronto, Canada. Additional data were presented from a study showing that increased vaccination rates may help prevent late-season influenza B outbreaks, as well as from a post-licensure safety analysis of FluMist that showed that the vaccine was well-tolerated.

"The results of the various FluMist-associated clinical and pharmacoeconomic studies presented at the PAS meeting are encouraging both individually and collectively," said Robert Walker, M.D., vice president, clinical development. "These data show us that innovative influenza vaccination approaches may have benefits that extend beyond just protection of the vaccinated individual. Immunizing children at places where they gather such as schools and daycare is logical, since children are often the main source of the spread of influenza in a community."

Cost-Effectiveness of Preventing Influenza in Young Children Attending Daycare Centers

Results from a previously completed and published placebo-controlled, two- season trial involving children aged 6 months to 36 months attending daycare centers showed that those children receiving FluMist experienced significantly fewer cases of influen
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Research Results on FluMist Presented at National Association of Pediatric Nurse Practitioners Conference
2. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
3. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
7. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
8. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
9. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
10. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
11. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
Post Your Comments:
(Date:11/26/2008)...swire/ -- Children whose eyes are misaligned and p...f developing mental illness by early adulthood, ac...hed this month in Pediatrics , the official journa... The retrospective study examined the medical rec...yes) and compared them with records of children ma...
(Date:11/25/2008)... , Audio and Web Video Resources to accompany ...log. Please see the bottom of this release for det...RNewswire-USNewswire/ -- A Mayo Clinic study shows... having a stroke -- and as a result -- delay seeki...ndings appear in the current issue of Emergency Me...
(Date:11/25/2008)...swire/ -- Proteolix, Inc., a,leader in the discov...get,protein degradation pathways in cancer and au... two ongoing Phase 2 clinical trials of carfilzomi...coming 50th Annual Meeting of the,American Societ...n a new class,of specific proteasome inhibitors a...
(Date:11/25/2008)...Assess Survival of Patients Receiving Litx versus ...cellular Carcinoma , , BELLEVUE, Wash., Nov... (LSO) today announced the completion of enrollmen...sion Therapy(TM) (Litx(TM)) as a treatment for unr...wn as hepatoma or primary liver cancer. , , ...
Breaking Medicine Technology:Eye Divergence in Children Triples Risk of Mental Illness 2Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Iomai CEO to Speak at BIO CEO 26 Investor Forum on Feb 12 3065 1Iomai CEO to Speak at BIO CEO 26 Investor Forum on Feb 12 3065 2Tourtellotte Solutions Fusion DMC 28TM 29 Unifies the World of Bio Pharma Documents 11110 1Tourtellotte Solutions Fusion DMC 28TM 29 Unifies the World of Bio Pharma Documents 11110 2Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies 3064 1Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies 3064 2Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies 3064 3Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 1Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 2Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 3Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 4Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 5Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 6Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 7Tutogen Medical Inc Reports First Quarter Fiscal 2008 Financial Results 3059 8
...--(BUSINESS WIRE)--Jun 6, 2007 - Inovio Biomedical...t of DNA vaccines,for cancers and infectious disea...calized cancers, announced today the company,deliv...esults and,new device innovations relating to its ...t the 10th Annual Meeting of the American,Society ...
...fficacy and Markers Demonstrated in Combination Tr...stCall/ --,EntreMed, Inc. , a clinical-stage pharm...y for the treatment of cancer and inflammatory,dis...from the Phase,1b study with Panzem(R) NCD (2ME2 o... (paclitaxel) in patients with metastatic,breast c...
Other Medicine Technology:Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting 2Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting 3Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting 4Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting 5Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer,Study Presented at ASCO 2Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer,Study Presented at ASCO 3Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer,Study Presented at ASCO 4
(Date:12/2/2008).... 2 In response to the commentary ...ent Respiratory Infections, and the Vitamin D Defi...well known supplement experts, Nordic Naturals ann...no threat or compromise to consumers and actually ...low in natural Vitamin A. According to Karin Yien,...
(Date:12/2/2008)...re/ -- The Healthcare group at Frost & Sulliva... to announce that it will be,hosting an interacti...diology,Markets on 11 December 2008 at 3pm GMT. ,...h/20081117/FSLOGO ) , With most diagnostic ...ndors in Europe are faced with an immense challeng...
(Date:12/2/2008)...Dec. 2 Internationally recognized,...nvited speaker for this,year,s annual meeting of ... (Photo: http://www.newscom.com/cgi-bin/prnh/200... minimally invasive (or ,Goldilocks,) anesthesia,...K 101, minimally invasive,anesthesia for minimall...
(Date:12/2/2008)... World Wide Dictation Service, one of the premier...cription, and legal dictation transcription, has ..., a non-profit organization geared to the betterme...r families throughout Lower Westchester County, Ne...WEB) December 3, 2008 -- World Wide Dictation Serv...
Breaking Medicine News(10 mins):Health News:Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy 2Health News:Will Diagnostic Cardiology Vendors Look to Product Innovation? 2Health News:World Wide Dictation Service Teams up with TMATT for Local Thanksgiving Community Dinner 2
...ity to develop 'much cheaper' drugs to combat HIV/...available first and second line treatment of the d...man in the country. Stating that the Indian compan...ging down the price of first and second line HIV d...
...om one evening in May, hoteliers, ambassadors, cel...ie gras, oysters and sushi while they talked about...skan king crab, French wine and melt-in-your-mouth...assembled crowd discussed ways of putting Bangkok ...
...t bread companies is not happy with the proposal t... acid. They are petitioning the state and federal/...e of such a proposal is to enhance the foliate lev... folic acid fortification will help offset birth d...
...er Surayud Chulanont, has defended his government'...ns of three patented// drugs-in spite of US worrie.... "We still defend what we have done, and we can ...ntries as well the world community," Surayud was q...
Other Medicine News:Health News:Bangkok Lures Visitors With Its Growing Gourmet Scene 2Health News:Thailand Unfazed As US Worries Over Copyright Violations 2
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: